Fig. 5: CT-179 efficacy in the G-Smo model.

A Western blots showing p-RB and p-OLIG2 in MBs from replicate G-Smo mice treated EOD from P10-P16 with CT-179 (80 mg/kg) or vehicle and harvested at P17, 24 hours after final dose with quantification below. The level of expression was normalized by β-actin (means ± SD, n = 3, p values by unpaired 2-tailed t-test). B Cell-cycle occupation analysis of MBs from replicate G-Smo mice treated with 80 mg/kg CT-179 and harvested after the indicated intervals, dissociated, and subjected to flow cytometry, compared to untreated controls (means ± SD, n = 3 for each group, p values: CT-179 24 h vs control: G0 = 0.00027, G1 = 0.0082, G2/M = 1.51e-05; CT-179 6 h vs control: G2/M = 0.020, p values by Dirichlet regression). (C and D) Quantification by flow cytometry of C G₂/M phase and D M phase cells, defined by very high p-RB⁺⁺ cells in dissociated MBs from CT-179-treated mice (means ± SD, n = 3, p values by 1-way ANOVA). E Representative NEUN/DAPI IHC and OLIG2/SOX10/DAPI IHC in G-Smo MB treated with CT-179 80 mg/kg or saline EOD P10-P16 and harvested at P17, with quantification of NEUN⁺ and OLIG2 + /SOX10- cells in tumors of replicate mice (means ± SD, n = 3, p values by unpaired 2-tailed t-test). F H&E of brains P17 G-Smo mice treated as in E with quantification of tumor cross-sectional area. (p values by 1-way ANOVA). G Kaplan–Meier curves of G-Smo mice on the CT-179 single-agent regimens, compared to untreated controls, (p values determined by Log-Rank test). H Kaplan–Meier curves of G-Smo mice on the indicated treatment regimens, showing the impact of combining radiotherapy and CT-179, (p values determined by Log-Rank test). A, C–F dots indicate individual biological replicates and columns indicate means. Source data are provided as Supplementary Data 4 Source Data file.